Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12735667 | 0.95 | S1PR1 (0.35) | S1PR1FFAR4CNR2FFAR1CNR1 | |
| SCHEMBL12735607 | 0.92 | CNR2 (0.35) | FFAR4CNR2FFAR1CNR1GABRA1 | |
| SCHEMBL12740120 | 0.92 | CNR2 (0.35) | FFAR4CNR2FFAR1CNR1GABRA1 | |
| SCHEMBL12740155 | 0.90 | FFAR4 (0.38) | S1PR1FFAR4CNR2FFAR1CNR1 | |
| SCHEMBL14766003 | 0.90 | S1PR1 (0.43) | S1PR1FFAR4CNR2FFAR1CNR1 | |
| SCHEMBL12738916 | 0.90 | GRM2 (0.35) | S1PR1CNR2CNR1CYP17A1 | |
| SCHEMBL12735665 | 0.89 | FFAR4 (0.36) | S1PR1FFAR4CNR2FFAR1CYP17A1 | |
| SCHEMBL12735656 | 0.88 | S1PR1 (0.47) | S1PR1FFAR4CNR2FFAR1CNR1 | |
| SCHEMBL10301959 | 0.88 | S1PR1 (0.37) | S1PR1CNR2CNR1CYP17A1GABRA1 | |
| SCHEMBL12740118 | 0.88 | FFAR4 (0.35) | FFAR4CNR2FFAR1CNR1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | S1PR1 1190/4885FFAR4 546/4885CNR2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.